Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central nervous program, conolidine modulates alternate molecular targets. A Science Advances review found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, whic